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Abstract
Background: Metastatic renal cell carcinoma has a poor prognosis and an intrinsic resistance to standard
treatment. Sunitinib is an oral receptor tyrosine kinase inhibitor that has been used as a first-line targeted
therapy in metastatic renal cell carcinoma. While computed tomography (CT) is currently the gold standard
for response assessment in oncological trials, numerous studies have shown that positron emission tomography
(PET) imaging can provide information predictive of tumor response to treatment earlier than the typical interval for
standard of care follow-up CT imaging. In this exploratory study we sought to characterize early tumor response in
patients with metastatic renal cell carcinoma treated with continuous daily 37.5 mg sunitinib therapy.
Methods: Twenty patients underwent dynamic acquisition positron emission tomography (PET) imaging using
18 F-fluorodeoxyglucose (FDG) and 18 F-fluorothymidine (FLT) at baseline and early in treatment (after 1, 2, 3
or 4 weeks) with 37.5 mg continuous daily dosing of sunitinib. Semi-quantitative analyses were performed to
characterize the tumor metabolic (FDG) and proliferative (FLT) responses to treatment.
Results: Proliferative responses were observed in 9/19 patients and occurred in 2 patients at one week (the
earliest interval evaluated) after the initiation of therapy. A metabolic response was observed in 5/19 patients,
however this was not observed until after two weeks of therapy were completed. Metabolic progression was
observed in 2/19 patients and proliferative progression was observed in 1/19 patients. Baseline FDG-PET
tumor maximum standardized uptake values correlated inversely with overall survival (p = 0.0036). Conversely,
baseline 18 F-fluorothymidine PET imaging did not have prognostic value (p = 0.56) but showed a greater early
response rate at 1–2 weeks after initiating therapy.
Conclusions: While preliminary in nature, these results show an immediate and sustained proliferative response
followed by a delayed metabolic response beginning after two weeks in metastatic renal cell carcinoma treated with
a continuous daily dose of 37.5 mg sunitinib. The results provide evidence of tumor response to lower-dose sunitinib
while also supporting the inclusion of PET imaging as a tool for early assessment in oncological clinical trials.
Trial registration: ID: NCT00694096
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Background
Sunitinib, a tyrosine kinase inhibitor that inhibits VEGF
receptor (types 1–3) and PDGF receptor (α and β), as well
as other tyrosine protein kinases;[1–4] is an approved treat-
ment of metastatic renal cell carcinoma (RCC). In an early
phase I trial including 4 patients with metastatic RCC, an
objective response was observed in 3 out of those
patients [5]. Phase II studies of sunitinib in 63 and 106
metastatic RCC patients revealed a partial response rate
of 36-40 % and a progression-free survival of 8.3-
8.7 months [6, 7]. A randomized phase III trial has
shown sunitinib to be superior to interferon-α in treat-
ment naïve patients with an objective response rate of
47 % (compared to 12 %) and a progression free sur-
vival of 11 months (compared to 5 months) [8]. In the
intermediate-risk group, median overall survival was
20.7 months with the treatment of sunitinib compared
to 15.4 months with interferon-α while the poor-risk
group had a median survival of 5.3 months with suniti-
nib compared to 4.0 months with interferon-α.
X-ray computed tomography (CT) is currently the gold
standard for response assessment in oncological clinical tri-
als and clinical practice [9, 10]. However, positron emission
tomography (PET) imaging with 18 F-fluorodeoxyglucose
(FDG) is also well-validated in the diagnosis, staging, and
response assessment of patients with cancer as the majority
of malignant tissues have increased FDG uptake associated
with an increased rate of glycolysis as well as increased glu-
cose transport [11, 12]. FDG-PET has been valuable in the
characterization and primary staging of solid renal masses
visualized by CT or MRI [13] and in the detection of dis-
tant metastasis in renal cancer [14]. For the evaluation of
metastases, investigations have found a range of sensitivities
from 60 % to 87 % and specificities close to 100 %, [15–17]
with a positive scan being predictive of the presence of dis-
ease in suspected metastases [18]. Finally, FDG-PET has
already shown efficacy for early response assessment in
therapeutic trials, including sunitinib therapy in gastrointes-
tinal stromal tumors [19].
Specifically in RCC, FDG-PET has shown utility in pre-
dicting response to sunitinib and other tyrosine kinase in-
hibitors in RCC when baseline studies are compared to
those after 4–16 weeks of treatment [20–23]. Farnebo, et al.
evaluated early response of metastatic RCC to treatment
with tyrosine kinase inhibitors using FDG-PET after 2 or
4 weeks of therapy and included 19 patients who received
sunitinib at 50 mg/day [24]. This study did show that
FDG-PET could successfully assess response at 2 weeks,
however, data from all tyrosine kinase inhibitors were
combined and analysis of patients only receiving sunitinib
was not reported.
18 F-fluorothymidine (FLT) is a structural analog of the
DNA constituent thymidine, which is not incorporated
into DNA, but instead is trapped intracellularly after
phosphorylation by thymidine kinase [25]. As such, FLT
has significant potential as an experimental radiolabeled
imaging agent to evaluate tumor cellular proliferation with
PET, [26, 27] To date, FLT has been utilized in numerous
published oncology trials to evaluate response to treat-
ment [28] and is known to have uptake in RCC [29]. A
study by Liu, et al. imaged 16 patients (seven with meta-
static RCC) receiving sunitinib therapy at baseline, the
end of a treatment cycle, and the end of drug withdrawal
cycle [30]. Sunitinib was administered in either a 4 weeks
on/2 weeks off or a 2 weeks on/1 week off schedule. This
study showed a reduction of proliferation during treat-
ment with marked increase in cellular proliferation during
the withdrawal phase.
Ideally, early phase clinical trials with novel targeted
chemotherapies should include investigation of the opti-
mal imaging strategy and timing for early assessment of
response to the novel therapeutic agents. The two previ-
ous studies to demonstrate the ability of FDG-PET [24]
and FLT-PET[30] to predict early response of metastatic
RCC to sunitinib administered with the standard dosing
regimen of 50 mg/day, 3 weeks on/1 week off. Here we
evaluate the utility of FDG-PET and FLT-PET for early
assessment of metabolic and proliferative response to treat-




This exploratory clinical trial (clinicaltrials.gov ID:
NCT00694096) was performed exclusively at the Hunts-
man Cancer Institute, University of Utah with institutional
review board approval. All patients signed informed con-
sent prior to enrollment. Patients were randomized to a 1,
2, 3, or 4 week treatment cohort at the time of consent.
Upon enrollment, the Response Evaluation Criteria in
Solid Tumors (RECIST 1.0) criteria [10] were used to
select appropriately sized target lesions from clinical CT
and/or magnetic resonance imaging (MRI) studies for fur-
ther evaluation with PET. In addition, the PET target
lesions were also required to be above background activ-
ity. Immediately after the completion of baseline PET
imaging, treatment was initiated with continuous oral
sunitinib at a dose of 37.5 mg/day. Early evaluation of dis-
ease response was performed by FDG-PET and FLT-PET
after approximately 1, 2, 3, or 4 weeks of continuous daily
treatment. Note that each patient only participated in a
single post-treatment scan so there were no intra-patient
comparisons at different time points.
Eligibility criteria
Inclusion criteria included: aged 18 or older, previous
histological diagnosis of RCC, documented evidence of
metastatic disease on contrast-enhanced CT and/or MRI
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within 30 days with at least one measurable lesion, [10] and
suitable candidacy for standard sunitinib therapy for meta-
static RCC as determined by the treating oncologist. Exclu-
sion criteria included: pregnancy or lactation (a negative
pregnancy test was required for premenopausal females);
renal insufficiency; known allergic or hypersensitivity reac-
tions to previously administered radiopharmaceuticals; HIV
positivity (as a precaution due to potential toxicity observed
with 3'-deoxy-3'-fluorothymidine (alovudine) in therapeutic
trials of HIV positive individuals [31]), and the requirement
of monitored anesthesia sedation for PET scanning.
Radiopharmaceuticals
FDG was manufactured locally in the PET Cyclotron
Radiochemistry Laboratory at the Huntsman Cancer
Institute under the practice of medicine and pharmacy.
FLT was synthesized by methods previously reported
[32, 33] and the FLT studies were conducted under an
FDA investigational new drug application held by JMH.
PET Imaging
All PET data were acquired using an Advance PET scanner
(GE Healthcare, Milwaukee, WI) in 2D mode in order to
minimize scatter and dead time. The patients were posi-
tioned such that the target lesion(s) were within a single
14.5 cm axial field of view. PET transmission scans were
acquired for 5–10 min using a rotating 68Germanium rod
source in order to perform attenuation correction. Follow-
ing the transmission scan, 277.5 MBq (7.5 mCi) of FDG or
185 MBq (5 mCi) of FLT was infused intravenously via a
peripheral vein over a period of one minute followed by a
saline flush in the arm opposite that from which blood
samples were subsequently drawn. At the time of radio-
tracer injection, a 70 min dynamic PET emission scan was
performed for a single bed position to facilitate future
exploratory kinetic analysis. A 20 min summed image was
generated from the dynamic images and used for the SUV
analysis in this study. Acquisitions were performed in 2D
mode with the exception of the baseline FLT-PET scan for
patient #9, which was inadvertently performed in 3D and
was excluded from the analysis. FDG- and FLT-PET scans
were performed on separate days, and typically on consecu-
tive days. Patients were fasted for 6 h prior to FDG scans to
reduce physiologic uptake in normal tissue. FLT-PET scans
were scheduled on the first day of imaging and patients
were also fasted to provide the opportunity for FDG-PET
imaging in the event of failed FLT production, as well as to
limit patient confusion in regard to preparation for the
scanning session.
FDG-PET and FLT-PET Semi-quantitative analysis
FDG-PET and FLT-PET images were reconstructed using
ordered-subsets expectation-maximization (OSEM) with 2
iterations and 28 subsets, and no post-reconstruction filter.
In one case (follow-up FDG-PET for patient# 16) re-
construction and raw data was lost due to computer
failure. Static images were computed using summed
data from the final dynamic time frames obtained at
50–70 min post-injection, representing a 60 min up-
take period with a +/−10 min window, which is con-
sistent with the NCI consensus recommendations for
measurement of standardized uptake values (SUVs) in
response assessment [12]. A region-of-interest (ROI)
was drawn around each target lesion previously iden-
tified on clinical CT or MRI that was contained
within the single PET bed position and confirmed to
have FDG and FLT uptake above background. Due to
the high liver uptake in FLT-PET studies, no liver le-
sions were selected. Each subject had a minimum of
1 target lesion on both FDG-PET and FLT-PET and
up to a maximum of 6 lesions. Side-by-side image review
and analysis was performed to assure that the regions
were obtained from the same lesions on baseline and
follow-up studies. Total body mass-corrected SUVs were
calculated for each ROI by normalizing for injected activ-
ity and body weight as follows: SUV = tissue concentration
(Bq/ml) X weight (g) / Dose (Bq). The maximum SUV
(SUVmax) for each ROI was determined. In individuals
with multiple target lesions, SUVmax values from each
ROI were summed to obtain a summed SUVmax, analogous
to the RECIST summed longest diameter [10]. This value
was then divided by the number of target lesions to obtain
the average SUVmax Metabolic response was assessed at the
follow-up PET scans using EORTC response criteria based
on the change in the follow-up average SUVmax relative to
baseline as follows: Progressive Disease (PD) ≥ 25 %
increase, Partial Response (PR) ≥ 25 % decrease, and Stable
Disease (SD) < 25 % change [34]. Similarly, proliferative
response were defined using the same +/−25 % thresholds
based on the relative changes in the FLT average SUVmax.
Statistical analysis
The goal of the statistical analysis was to evaluate base-
line FDG-PET and FLT-PET variables to overall survival
and compare differences in early versus late response
rates across the different cohorts with both PET radio-
pharmaceuticals. Overall survival was measured from
the beginning of treatment. The per-patient average of
the baseline FDG and FLT SUVmax was calculated by
dividing the summed SUVmax of all target lesions for a
given subject by the number of lesions. The total data
set has 20 subjects with 4, 7, 5 and 4 subjects in the 1, 2,
3 and 4-week treatment cohorts respectively. All cohorts
were analyzed together with clustering by cohort as the
sample sizes were too small to analyze the cohorts separ-
ately. Cox proportional hazards models with robust
standard errors accounting for small sample sizes [35]
were used to analyze overall survival. The two predictor
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variables analyzed in this study consisted of baseline
average SUVmax for both FDG-PET and FLT-PET. These
predictor variables were treated as continuous predictors.
The Benjamini and Hochberg method was used to adjust
the p-values for multiple comparisons [36]. Kaplan-Meier
methods were used to plot overall survival with the pre-
dictors dichotomized at the median. Logistic regression
and the associated likelihood ratio test were used to
test for a trend in response with group. Group was
considered as a continuous variable with values 1, 2,
3, and 4 representing the weeks of treatment for each
cohort. The statistical analysis was performed using R
3.0.2 statistical computing software (R development
Core Team, 2013) [37].
Results
Patient population
From November 2007 to March 2012, 25 patients were
enrolled in this study at the University of Utah Huntsman
Cancer Institute. Twenty patients completed PET imaging
at both time points and were considered evaluable for this
study (completed both baseline and follow-up PET imaging
assessments). Of the 5 patients not considered evaluable,
one was unable to complete a 70 min imaging session due
to pain and 3 did not return for post-treatment PET
imaging due to transfer of care or being lost to follow-up.
The one remaining patient did complete both PET imaging
sessions, however, was found to have pathologically proven
sarcoidosis at the location of PET imaging after undergoing
surgical resection one week after completing the
follow-up PET imaging assessment. The 20 patients in-
cluded in this study were composed of 14 (70 %) males
aged 50—76 (mean 63.6) years and 6 females aged
67—86 (mean 75) years (Table 1). One to six (mean
2.3) target lesions were identified per patient on clinical
CT or MRI using RECIST 1.0 size criteria [10] and
evaluated with subsequent PET imaging. Eighteen pa-
tients were naïve to prior systemic therapy prior to this
study with the remaining two patients having failed IL-2
therapy. Fifteen patients had undergone nephrectomy
prior to enrolling into this trial. FLT-PET and FDG-PET
imaging studies were almost exclusively performed on
consecutive days, however in two instances baseline FDG
and FLT scans were performed 4 and 7 days apart due to
patient scheduling conflicts and technical difficulties with
radiotracer production, respectively. Four individuals had
documentation of missed doses of sunitinib during the
study period; the total number of missed doses for those
individuals were: 1, 2, 2.5, and 5. The number of days
on treatment and overall survival are summarized in
Table 1. Due to drug-related adverse events and other
clinical factors, many patients did not continue therapy
for the total duration of their survival after the
completion of imaging. As a result, survival analysis
could not be performed using the post-treatment im-
aging results as a predictive biomarker.
Early assessment of metabolic response with semi-
quantitative FDG-PET
The target lesions identified on previous clinical imaging
were associated with FDG uptake on both baseline and
follow-up PET imaging in all patients (Fig. 1). The aver-
age SUVmax as baseline and follow-up for each subject is
summarized in Table 2. A metabolic response (reduction
in tumor metabolism of ≥ 25 % as measured with FDG-
PET) was observed in 5/19 (26 %) of patients; with 0, 1,
2, and 2 patients at 1, 2, 3, and 4 weeks, respectively
(Fig. 2, Table 3). Metabolic disease progression (increase
in tumor metabolism of ≥ 25 % as measured with
FDG-PET) was observed in 2/19 (11 %) of patients;
with 1, 0, 0, and 1 patients at 1, 2, 3, and 4 weeks,
respectively. Interestingly, tumor metabolic response
appeared to be delayed and was not observed until
after at least 2 weeks of continuous lower-dose suni-
tinib therapy. This effect was confirmed as a
significant trend in metabolic response with increas-
ing weeks of treatment (cohorts) (likelihood ratio chi-
square = 4.00, p = 0.045).
Table 1 Study patient population and clinical outcome




14 67 F Clear Cell 1518 1687
24 62 M Clear Cell 565 1040
20 63 M Clear Cell 1390 1390
5 60 M Clear Cell 56 480
2 50 M Mixed 9 2399
21 59 M Clear Cell 1145 1390
22 65 M Papillary 205 347
19 57 M Clear Cell 84 262
23 67 F Papillary 1064 1207
25 71 M Clear Cell 27 27
18 76 F Clear Cell 10 216
9 72 F Mixed 33 98
15 86 F Clear Cell 25 142
16 59 M Clear Cell 29 183
11 70 M Chromophobe 735 1756
17 68 M Clear Cell 118 463
6 61 M Clear Cell 400 1519
8 76 M Clear Cell 133 791
10 69 M Clear Cell 141 803
4 82 F Unknown 30 544
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Early assessment of proliferative response with semi-
quantitative FLT-PET
Similarly to FDG, the target lesions identified on previous
clinical imaging were associated with FLT uptake on both
baseline and follow-up PET imaging in all patients (Fig. 3).
A partial proliferative response (reduction in tumor prolif-
eration of ≥ 25 % as measured with FLT-PET) was observed
in 9/19 (47 %) of patients; with 2, 3, 2, and 2 patients at 1,
2, 3, and 4 weeks, respectively (Fig. 4, Table 3). Proliferative
disease progression (increase in tumor proliferation of ≥
25 % as measured with FLT-PET) was observed in 1/19
(5 %) of patients; with 0, 0, 1, and 0 patients at 1, 2, 3, and
4 weeks, respectively. Unlike metabolic responses measured
with FDG-PET, tumor proliferative response to continuous
Fig. 1 FDG-PET images illustrating a metabolic response to 37.5 mg daily sunitinib treatment. Single slice coronal inverted grayscale (a, b) and
21-step color (c, d) FDG-PET images from a patient (ID#6) showing a metabolic response to lower-dose sunitinib in a right upper lobe lung
lesion (circles). a, c: Baseline images prior to initiation of therapy with sunitinib. b, d: Follow-up images obtained after 28 days of treatment
with lower-dose sunitinib. Circles mark the location of the tumor to distinguish it from the normal cardiac and hepatic uptake




















14 Week 1 4.9 6.2 PD 6.9 8.4 SD
24 Week 1 5.1 5.8 SD 5.5 5.9 SD
20 Week 1 5.2 6.4 SD 7.4 5.3 PR
5 Week 1 4.9 5.3 SD 4.5 2.8 PR
2 Week 2 4.7 5.6 SD 4.7 4.5 SD
21 Week 2 3.4 3.5 SD 6.2 3.1 PR
22 Week 2 8.7 9.3 SD 6.8 6.7 SD
19 Week 2 17.9 15.0 SD 7.8 5.6 PR
23 Week 2 18.1 12.5 PR 5.0 5.3 SD
25 Week 2 9.6 9.0 SD 5.8 6.2 SD
18 Week 2 12.6 12.2 SD 8.4 5.1 PR
9 Week 3 21.0 15.8 SD N/A 5.3 N/A
15 Week 3 6.0 4.2 PR 3.4 2.5 PR
16 Week 3 10.9 N/A N/A 9.7 12.7 PD
11 Week 3 2.7 3.2 SD 1.3 1.4 SD
17 Week 3 1.5 1.0 PR 0.7 0.4 PR
6 Week 4 7.3 5.2 PR 5.1 2.1 PR
8 Week 4 8.9 7.1 SD 14.6 7.5 PR
10 Week 4 4.9 6.7 PD 5.1 5.9 SD
4 Week 4 7.0 4.9 PR 5.3 5.0 SD
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lower-dose sunitinib was not delayed as it was ob-
served at the earliest interval of follow-up (1 week)
and appeared to remain stable throughout the entire
period of observation for this study with similar response
rates for each cohort. In contrast to FDG-PET, there is no
trend in proliferative response with FLT-PET across cohorts
with increasing weeks of treatment (likelihood ratio chi-
square = 0.01, p = 0.93).
Baseline FDG and FLT average SUVmax as predictors of
survival
As expected, higher baseline FDG-PET average SUVmax
values correlated with shorter overall survival (p = 0.0036,
Table 4, Fig. 5a,), indicating prognostic value for early
assessment with FDG-PET in this study of patients with
metastatic RCC. In contrast, baseline FLT-PET did not
have prognostic value in this study as the baseline FLT-
PET average SUVmax values did not correlate with overall
survival (p = 0.56, Table 4, Fig. 5b).
Disscussion
Here we provide evidence that PET imaging may be a valu-
able tool in the early assessment of response to continuous
treatment with sunitinib in metastatic RCC. Despite the
small sample size in this exploratory study, baseline FDG-
PET SUVmax was prognostic of overall survival. Conversely,
correlations of baseline FLT-PET semi-quantitative mea-
sures with overall survival were not statistically significant
in this study. This would suggest that tumor metabolism
may be more useful for the assessment of disease burden
and/or tumor aggressiveness than the rate of proliferation
in this setting. In other studies however, semi-quantitative
PET measures such as SUVmax have shown prognostic
value in many cancer types using multiple radiotracers [38].
Additional PET imaging studies in metastatic RCC compar-
ing FDG-PET and FLT-PET will be needed before definitive
conclusions can be drawn.
Reductions in both tumor metabolism and proliferation
in response to continuous lower-dose sunitinib were ob-
served with PET using FDG and FLT, respectively. Interest-
ingly, the timing of these responses were somewhat offset.
Proliferative response to continuous lower-dose sunitinib
was noted early in the treatment course, after 1 week of
therapy (the earliest interval of observation), and remained
constant throughout the duration of the study. Conversely,
metabolic responses were relatively delayed, not being
Fig. 2 Metabolic tumor response to 37.5 mg daily sunitinib over time as measured with FDG-PET. Graphs illustrating the percent change in FDG
SUVmax from pre-treatment baseline to after 1 (a), 2 (b), 3 (c), or 4 (d) weeks of sunitinib therapy in individual patients. There was a delayed
metabolic response to continuous lower-dose sunitinib beginning after two weeks of treatment that was maintained throughout the duration of
this study. Green bars represent metabolic response (≥25 % decrease in FDG SUVmax), red bars represent metabolic progression (≥25 % increase
in FDG SUVmax), and blue bars represent stable disease (<25 % change in SUVmax). The bars are labeled with the corresponding patient study
identification number
Table 3 PET Imaging Response Rates
Treatment Metabolic Assessment Proliferative Assessment
Cohort PR SD PD PR SD PD
Week 1 0/4 (0 %) 3/4 (75 %) 1/4 (25 %) 2/4 (50 %) 2/4 (50 %) 0/4 (0 %)
Week 2 1/7 (14 %) 6/7 (86 %) 0/7 (0 %) 3/7 (43 %) 4/7 (57 %) 0/7 (0 %)
Week 3 2/4 (50 %) 2/4 (50 %) 0/4 (0 %) 2/4 (50 %) 1/4 (25 %) 1/4 (25 %)
Week 4 2/4 (50 %) 1/4 (25 %) 1/4 (25 %) 2/4 (50 %) 2/4 (50 %) 0/4 (0 %)
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observed until after at least 2 weeks of treatment. This
suggests that inhibition of VEGF and PDGF signaling with
sunitinib exerts an early effect on tumor proliferation, [39]
which is then followed by a reduction in tumor metabolism.
However, due to the fact that patients did not undergo
imaging at multiple time points during treatment in this
study and the small number of subjects, we cannot rule out
that the chronology of the PET findings were an artifact of
individual patient responses. Farnebo, et al. did observe a
maintained reduction in FDG uptake in patients imaged
after 2 and 4 weeks of treatment, indicating that the lack of
repeat imaging in our study could be biasing our results,
however, that study included patients treated with other
tyrosine kinase inhibitors and their data were not stratified
based upon treatment agent [24]. Of note, our study
assessed only the earliest response to treatment (1–4
weeks) and it is not known whether or not the reduction
in tumor metabolism is transient or maintained, or if later
effects on tumor proliferation also occur. Previous work
evaluating response to treatment with sunitinib in meta-
static RCC has shown that reductions in tumor metabol-
ism detected with FDG-PET are maintained for up to
16 weeks [20–22]. However, the prevalence of metabolic
responders is reduced at later time points,[20] indicating
Fig. 3 FLT-PET images illustrating a proliferative response to 37.5 mg daily sunitinib treatment. Single slice coronal inverted grayscale (a, b) and
21-step color (c, d) FLT-PET images from the same patient as in Fig. 1 (ID#6) showing a proliferative response to lower-dose sunitinib in a right
upper lobe lung lesion (circles). a, c: Baseline images prior to initiation of therapy with sunitinib. b, d: Follow-up images obtained after 28 days of
treatment with lower-dose sunitinib. Circles mark the location of the tumor to distinguish it from the normal skeletal and hepatic uptake
Fig. 4 Proliferative tumor response to 37.5 mg daily sunitinib over time measured with FLT-PET. Graphs illustrating the percent change in FLT
SUVmax from pre-treatment baseline to after 1 (a), 2 (b), 3 (c), or 4 (d) weeks of sunitinib therapy in individual patients. There was an immediate
proliferative response to continuous lower-dose sunitinib that was maintained throughout the duration of this study. Green bars represent
proliferative response (≥25 % decrease in FLTSUVmax), red bars represent proliferative progression (≥25 % increase in FLT SUVmax), and blue bars
represent stable disease (<25 % change in SUVmax). The bars are labeled with the corresponding patient study identification number
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that tumor resistance to sunitinib may develop after the
period of observation captured in our study and that early
response may not be indicative of overall outcome. Liu, et
al. conducted a study in which patients were imaged with
FLT-PET after either 2 or 4 weeks of treatment with suni-
tinib, however, this study focused on the effects of the
standard drug holiday on tumor proliferation and revealed
a significant increase in tumor proliferation off drug [30].
The post-treatment imaging and response assessment
could not be compared to survival due to the limited pa-
tient numbers and lack of compliance in continuing treat-
ment after the follow-up imaging time point. Many
patients discontinued sunitinib therapy shortly after their
follow-up PET imaging and went on other subsequent
therapies. For these reasons, it cannot be assessed whether
the differences seen in early imaging response with FDG-
PET and FLT-PET are predictive of survival. It is possible
that FLT-PET and FDG-PET can still be used as
pharmacodynamic biomarkers at the appropriate timing
during treatment without predicting the overall survival.
An obvious limitation of our study was the use of a
PET-only tomograph. We were not able to assess whether
or not response to treatment as measured with PET corre-
sponded to RECIST changes with anatomic imaging as
CT scans were not performed at the time of PET imaging.
Standard of care clinical CTs were obtained at varying
intervals, however, these images were obtained weeks to
months after the conclusion of our PET imaging study as
some patients did not continue treatment with sunitinib
and those CTs were obtained prior to beginning a new
type of therapy.
Conclusions
The results of this study, while exploratory in nature,
suggest that PET imaging with both FDG and FLT has
utility in the early evaluation of response to treatment in
Table 4 Results of Cox Proportional Hazards Models – Continuous Predictors
Predictor Coefficient Hazard Ratio Robust
Standard
Error (se)
















0.033022 1.033573 0.056237 0.587196 0.557072332 0.56
Fig. 5 Baseline average FDG-PET SUVmax is predictive of overall survival. Kaplan-Meier plots of baseline FDG average SUVmax (a) and baseline FLT
average SUVmax (b) as a predictor of overall survival. The baseline FDG average SUVmax was predictive of overall survival with higher SUVmax values
correlated with shorter overall survival (p = 0.0036). Conversely, the baseline FLT average SUVmax did correlate with overall survival (p = 0.56)
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metastatic RCC. While FLT-PET could be used to identify
response as early as 1 week after starting treatment, our
results suggest FDG-PET is more effective at later time
points of 3–4 weeks. Additional studies with longer treat-
ment duration are needed to more fully characterize the
metabolic and proliferative responses in the context of
predicting post treatment survival. Despite the limited
subject numbers of this study, the baseline FDG-PET aver-
age SUVmax was a prognostic predictor of survival. More
broadly, this study underscores the importance for the
inclusion of early PET imaging assessments in clinical
studies to define the best imaging approach for early
therapeutic assessment in targeted therapies. The on-
going evolution of PET/CT imaging will continue to
improve the assessment of physiologic and biologic
parameters as well as to facilitate improved accuracy of
lesion size measurement with concurrent CT imaging.
Defining the best imaging modalities for early thera-
peutic assessment of response or treatment failure will
allow for a more streamlined, cost effective and person-
alized approach to cancer patient care.
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